 | Up a level |
Journal Article
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A. D., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive (NTRK-fp) Tumors: Pooled analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Demetri, G. D., Paz-Ares, L., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Kim, E. S., Blakely, C. M., Krauss, J. C., Sigal, D., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Chow-Maneval, E., Multani, P. S., Johnson, A., Simmons, B. and Doebele, R. C. (2018). Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann. Oncol., 29. S. 175 - 176. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Drilon, A., Paz-Ares, L., Doebele, R. C., Farago, A. F., Liu, S. V., Chawla, S. P., Tosi, D., Blakely, C. M., Krauss, J. C., Bazhenova, L., John, T., Besse, B., Wolf, J., Seto, T., Cho, B. C., Rolfo, C., Osborne, S., Aziez, A. and Demetri, G. D. (2020). Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann. Oncol., 31. S. S474 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Wolf, J., Liu, S. V., Paz-Ares, L., Hu, J., Cho, B. C., Krzakowski, M., Chung, C. H., Patel, M., Taylor, M., Zeuner, H., Aziez, A., Huang, X., Osborne, S. and Farago, A. (2020). Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001. Oncol. Res. Treat., 43 (SUPPL 4). S. 34 - 35. BASEL: KARGER. ISSN 2296-5262